Evaluating the druggability of TrmD, a potential antibacterial target, through design and microbiological profiling of a series of potent TrmD inhibitors

Bioorg Med Chem Lett. 2023 Jun 15:90:129331. doi: 10.1016/j.bmcl.2023.129331. Epub 2023 May 13.

Abstract

The post-transcriptional modifier tRNA-(N1G37) methyltransferase (TrmD) has been proposed to be essential for growth in many Gram-negative and Gram-positive pathogens, however previously reported inhibitors show only weak antibacterial activity. In this work, optimisation of fragment hits resulted in compounds with low nanomolar TrmD inhibition incorporating features designed to enhance bacterial permeability and covering a range of physicochemical space. The resulting lack of significant antibacterial activity suggests that whilst TrmD is highly ligandable, its essentiality and druggability are called into question.

Keywords: Anti-infectives; Azaindole derivatives; Nicotinamide derivatives; Structure-based design; TrmD; tRNA-(N(1)G37) Methyltransferase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Bacteria
  • Methyltransferases*
  • tRNA Methyltransferases* / chemistry

Substances

  • tRNA Methyltransferases
  • Methyltransferases
  • Anti-Bacterial Agents